Syndax Pharmaceuticals (NASDAQ:SNDX) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.
Valuation & Earnings
This table compares Syndax Pharmaceuticals and Turning Point Therapeutics' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Syndax Pharmaceuticals | $1.52 million | 703.23 | $-56,050,000.00 | ($1.84) | -12.04 |
Turning Point Therapeutics | N/A | N/A | $-72,130,000.00 | ($2.99) | -26.40 |
Syndax Pharmaceuticals has higher revenue and earnings than Turning Point Therapeutics. Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and price targets for Syndax Pharmaceuticals and Turning Point Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Syndax Pharmaceuticals | 0 | 2 | 9 | 0 | 2.82 |
Turning Point Therapeutics | 0 | 0 | 7 | 0 | 3.00 |
Syndax Pharmaceuticals presently has a consensus target price of $28.5455, suggesting a potential upside of 28.82%. Turning Point Therapeutics has a consensus target price of $153.7143, suggesting a potential upside of 94.70%. Given Turning Point Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Turning Point Therapeutics is more favorable than Syndax Pharmaceuticals.
Risk and Volatility
Syndax Pharmaceuticals has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.
Insider and Institutional Ownership
83.8% of Syndax Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are owned by institutional investors. 9.5% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Syndax Pharmaceuticals and Turning Point Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Syndax Pharmaceuticals | -4,656.63% | -77.47% | -52.27% |
Turning Point Therapeutics | N/A | -23.81% | -23.08% |
Summary
Syndax Pharmaceuticals beats Turning Point Therapeutics on 7 of the 13 factors compared between the two stocks.